Leo International Precision Health Aktiengesellschaft
0.06
EUR
-0.01
(-17.81%)
ISIN
DE0005490601
Return %
Stock
S&P 500
1Y
0.92
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- Sector
- Finance
- Industry
- Financial conglomerates
- Address
- Garching Germany
- IPO Date
- Jun 1, 2001
- Website
- spobag-ag.de
- Similar Companies
- Business
- Leo International Precision Health Aktiengesellschaft operates as an integrated life sciences and healthcare investment holding company dedicated to the development and commercialization of artificial intelligence-driven diagnostics, biotechnology, medical technology, and longevity solutions. Originally incorporated in 1999 and headquartered in Planegg/Martinsried near Munich, Germany, the company manages an international ecosystem of operational subsidiaries spanning North America, Europe, and the Asia-Pacific region, including active entities in the United States, Singapore, Taiwan, Hong Kong, and Australia. The company delivers a diversified portfolio of clinical, diagnostic, and therapeutic products and services organized across four core business segments: Biotechnology, MedTech, HealthTech, and Healthcare Services. Its principal offerings include artificial intelligence-powered biomedical discovery and diagnostic platforms, notably the amiko AI Co-Scientist system for large-language-model-based biomedical intelligence, drug repurposing, and diagnostic acceleration; molecular pathology and clinical laboratory diagnostics provided through Danner Laboratory, Inc., featuring CTCReveal liquid biopsy assays, CellBio artificial intelligence-enhanced cytopathology imaging, and comprehensive oncological screening tests; precision multi-omics profiling and digital preventative healthcare solutions developed by Pathomics Health Pte. Ltd., encompassing the PathGene genetic screening panels and the P7 Health digital patient management and risk prediction architecture; specialized clinical pain management and outpatient rehabilitation services operated under the Dr. PAIN brand by Wankang Medical Group, which combines physiotherapy, Traditional Chinese Medicine, and data-driven diagnostic monitoring; oncological recovery nutraceuticals and targeted immune-support formulations manufactured by Immune Anima Inc. under the UHO Wellness line; and certified cellular longevity therapeutics and nutritional supplements produced by Renhe Biotech (Australia) Pty Ltd, with an emphasis on pharmaceutical-grade nicotinamide adenine dinucleotide (NAD+) healthy aging formulations. In recent corporate developments, the company completed a comprehensive restructuring and reverse takeover in 2025 following the acquisition of a controlling stake by an investment consortium led by Chairman Hsiao-Hsuan "Leo" Wang. Under this strategic realignment, the entity was rebranded from SPOBAG Aktiengesellschaft to Leo International Precision Health Aktiengesellschaft. In December 2025, the company finalized a capital increase in kind valued at approximately EUR 111 million, formally integrating six international operating subsidiaries—Danner Laboratory, Inc., Immune Anima Inc., Pathomics Health Pte. Ltd., Rehne Biotech (Australia) Pty Ltd, amiko AI Biomedical Limited, and Wankang Medical Group (Hong Kong) Co., Limited—into its listed corporate structure on the Frankfurt Stock Exchange (XETRA: LEOW). In mid-2026, the company resolved legacy administrative reporting requirements with the German Federal Financial Supervisory Authority (BaFin), completing its transition into an active, globally deployed precision healthcare and artificial intelligence life sciences enterprise.